DDInter1215 DDInter856
Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Mifepristone {u} (Compound) binds {v} (Gene) CYP3A5
Mifepristone {u} (Compound) upregulates {v} (Gene) CDK6
Mifepristone {u} (Compound) is included by {v} (Pharmacologic Class) Progestational Hormone Receptor Antagonists
Mifepristone {u} (Compound) downregulates {v} (Gene) ATP6V1D
Mifepristone {u} (Compound) causes {v} (Side Effect) Toxic shock syndrome
Mifepristone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Mifepristone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Mifepristone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naldemedine
Mifepristone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Mifepristone {u} may lead to a major life threatening interaction when taken with {v} Daunorubicin
Mifepristone (Compound) binds CYP3A5 (Gene)
Mifepristone (Compound) upregulates CDK6 (Gene)
Mifepristone (Compound) is included by Progestational Hormone Receptor Antagonists (Pharmacologic Class)
Mifepristone (Compound) downregulates ATP6V1D (Gene)
Mifepristone (Compound) causes Toxic shock syndrome (Side Effect)
Mifepristone may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Mifepristone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol
Mifepristone may lead to a major life threatening interaction when taken with Daunorubicin